Status:
UNKNOWN
Artificial Intelligence With Deep Learning and Genes on Cardiovascular Disease
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
An association study with large database from electronic medical record system, images, outcome analysis and genetic single nucleotide polymorphism variations by machine learning and artificial intell...
Detailed Description
In recent years, the analysis of big data database combined with computer deep learning has gradually played an important role in biomedical technology. For a large number of medical record data analy...
Eligibility Criteria
Inclusion
- Patients' selection criteria and enrollment plan:
- We will enroll subjects from either cardiovascular clinics or inpatients from the National Cheng Kung University Hospital from 2018 to 2021 after the signature of inform consent from patients and their families. The major enrollment criteria include one of the flowing diseases or conditions:
- A. Coronary artery disease:
- History of myocardial infarction
- Coronary artery disease with computer tomography angiography image study with at least one vessel luminal stenosis \>70%
- Coronary artery stents implantation by hospital-based image database
- Thallium-201 scan positive/treadmill test positive with additional 2 risk factors, including
- Diabetes mellitus
- Hypertension
- Dyslipidemia
- Family history of sudden death, coronary bypass surgery, cerebral vascular attacks (CVA), premature myocardial infarction
- Smoking behaviors
- B. Congestive heart failure with reduced ejection fraction
- 1\. Echocardiography left ventricular ejection fraction \<40%
- C. Hypertrophic cardiomyopathy:
- Left ventricle interventricular septum（IVS) \>15 mm
- Left ventricle mass index\> 200gm
- Apical hypertrophy noted on the report with 4 chamber view
- D. Atrial fibrillation
- Recorded by Holter continuous EKG
- Recorded by standard 12 leads complete EKG
- E. Pulmonary hypertension
- Echo with systolic pulmonary pressure (sysPAP)\> 40 mmHg
- Diagnosis of idiopathic pulmonary hypertension
- Under pulmonary hypertension medication
- F. Fabry's disease
- α-Galactosidase (a-GAL) enzyme deficiency
- Genetic disorder
- G. Patient with only risk factors (\<3 risk factors), recognized as the comparison group (\>500 cases)
- Diabetes mellitus
- Hypertension
- Dyslipidemia
- Family history of sudden death, coronary bypass surgery, cerebral vascular attacks, premature myocardial infarction
- Smoking behavior
Exclusion
- Patients unwilling to be enrolled
- Concentration of DNA collection was inadequate after 3 times of collection
Key Trial Info
Start Date :
August 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT03877614
Start Date
August 28 2018
End Date
June 1 2022
Last Update
March 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, National Cheng Kung University Hospital
Tainan, Taiwan, 704